MeSH term
Frequency | Condition_Probility | Aged | 101 | 0.0 |
Aged, 80 and over | 18 | 0.0 |
Female | 171 | 0.0 |
Humans | 461 | 0.0 |
*Blood Coagulation | 12 | 5.0 |
Blood Coagulation Factors/metabolism | 3 | 5.0 |
Blood Coagulation Tests | 6 | 3.0 |
Case-Control Studies | 8 | 0.0 |
Diabetic Angiopathies/*blood | 2 | 9.0 |
*Hemostasis | 8 | 6.0 |
Male | 196 | 0.0 |
Middle Aged | 172 | 0.0 |
Animals | 90 | 0.0 |
Binding, Competitive | 4 | 0.0 |
Cells, Cultured | 27 | 0.0 |
Dose-Response Relationship, Drug | 22 | 0.0 |
Hamsters | 6 | 0.0 |
Platelet Factor 4/*metabolism/*pharmacology | 2 | 100.0 |
Research Support, U.S. Gov't, P.H.S. | 110 | 0.0 |
Adenosine Diphosphate/pharmacology | 10 | 8.0 |
Bleeding Time | 4 | 3.0 |
Calcium/blood | 2 | 0.0 |
Collagen/pharmacology | 4 | 3.0 |
Epinephrine/pharmacology | 6 | 6.0 |
Freeze Fracturing | 2 | 8.0 |
Platelet Activation/drug effects | 7 | 11.0 |
Platelet Aggregation | 21 | 12.0 |
Platelet Function Tests | 10 | 24.0 |
Ristocetin/pharmacology | 2 | 1.0 |
von Willebrand Factor/analysis | 5 | 1.0 |
Platelet Activation | 12 | 8.0 |
Antibodies/*blood | 4 | 8.0 |
Catheters, Indwelling/*adverse effects | 2 | 25.0 |
Platelet Factor 4/*immunology/metabolism | 3 | 100.0 |
Prospective Studies | 16 | 0.0 |
Recurrence | 3 | 0.0 |
*Renal Dialysis | 10 | 2.0 |
Research Support, Non-U.S. Gov't | 193 | 0.0 |
Amino Acid Sequence | 34 | 0.0 |
Antibody Specificity | 6 | 0.0 |
Heparin/adverse effects/*immunology | 7 | 100.0 |
Mice | 32 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Thrombocytopenia/chemically induced/*immunology | 7 | 100.0 |
Thrombosis/chemically induced/*immunology | 4 | 100.0 |
Apoptosis/drug effects | 2 | 0.0 |
Cattle | 12 | 0.0 |
Cell Division/drug effects | 7 | 0.0 |
Molecular Sequence Data | 41 | 0.0 |
Platelet Factor 4/chemistry | 2 | 100.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 13 | 0.0 |
Structure-Activity Relationship | 10 | 0.0 |
Blood Preservation | 3 | 4.0 |
Cardiopulmonary Bypass/*instrumentation | 2 | 15.0 |
Cell Survival/drug effects | 5 | 0.0 |
Complement Activation | 2 | 0.0 |
Hemostasis | 3 | 2.0 |
Antibodies/*immunology | 3 | 2.0 |
Anticoagulants/*adverse effects | 5 | 55.0 |
Endothelium, Vascular/*cytology | 3 | 1.0 |
Heparin/*adverse effects/immunology | 9 | 90.0 |
Microcirculation | 2 | 0.0 |
Platelet Factor 4/*immunology | 7 | 87.0 |
Thrombocytopenia/*chemically induced/immunology | 2 | 100.0 |
Adult | 170 | 0.0 |
Platelet Factor 4/*metabolism | 25 | 92.0 |
Blood Platelets/*pathology | 3 | 20.0 |
Enzyme-Linked Immunosorbent Assay | 20 | 0.0 |
Platelet Factor 4/*biosynthesis | 3 | 75.0 |
Time Factors | 18 | 0.0 |
Transforming Growth Factor beta/*blood | 3 | 11.0 |
Blood Platelets/*metabolism | 16 | 5.0 |
P-Selectin/blood | 2 | 3.0 |
Platelet Factor 4/metabolism | 47 | 81.0 |
Reference Values | 19 | 0.0 |
Transplantation, Autologous | 2 | 0.0 |
Veins | 2 | 3.0 |
Pregnancy | 5 | 0.0 |
Thrombosis/*etiology | 2 | 4.0 |
Blotting, Western | 4 | 0.0 |
Heparin/*adverse effects | 7 | 58.0 |
*Cell Adhesion | 2 | 1.0 |
Flow Cytometry | 5 | 0.0 |
In Vitro | 28 | 0.0 |
*Platelet Activation | 20 | 14.0 |
Platelet Factor 4/pharmacology | 4 | 50.0 |
Thrombocytopenia/chemically induced/complications/*immunology | 2 | 100.0 |
Thrombosis/etiology | 2 | 3.0 |
Base Sequence | 19 | 0.0 |
Binding Sites | 6 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
Megakaryocytes/*metabolism | 4 | 12.0 |
Mice, Transgenic | 4 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Fibrinolytic Agents/blood | 2 | 16.0 |
Platelet Activation/immunology | 4 | 36.0 |
Platelet Factor 4/chemistry/*immunology | 2 | 100.0 |
Cellulose/analogs & derivatives | 3 | 10.0 |
Comparative Study | 98 | 0.0 |
*Membranes, Artificial | 6 | 7.0 |
Platelet Factor 4/analysis | 69 | 87.0 |
Polymers | 2 | 1.0 |
Sulfones | 2 | 10.0 |
beta-Thromboglobulin/metabolism | 36 | 64.0 |
Biological Markers/analysis | 3 | 0.0 |
Fibrinolysis/physiology | 2 | 4.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/metabolism | 2 | 5.0 |
Prothrombin/metabolism | 2 | 2.0 |
Thrombin/metabolism | 4 | 2.0 |
Blood Platelets/*drug effects/metabolism | 2 | 5.0 |
Cell Degranulation/drug effects | 2 | 9.0 |
Antibodies, Monoclonal | 6 | 0.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Models, Molecular | 4 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Protein Binding | 12 | 0.0 |
Swine | 5 | 0.0 |
Carbohydrate Sequence | 3 | 0.0 |
Heparin Lyase/pharmacology | 2 | 15.0 |
Thrombin/antagonists & inhibitors | 4 | 16.0 |
English Abstract | 40 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Cloning, Molecular | 8 | 0.0 |
Dose-Response Relationship, Immunologic | 2 | 0.0 |
Drug Synergism | 3 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Reproducibility of Results | 3 | 0.0 |
Platelet Activation/*physiology | 7 | 12.0 |
Thrombin/*physiology | 3 | 14.0 |
*Thrombin Time | 2 | 100.0 |
Blood Flow Velocity | 2 | 2.0 |
Blood Pressure | 4 | 0.0 |
Statistics, Nonparametric | 4 | 0.0 |
Surface Properties | 6 | 3.0 |
beta-Thromboglobulin/analysis | 58 | 70.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Growth Substances/metabolism | 2 | 1.0 |
Mutation | 3 | 0.0 |
*Neovascularization, Pathologic | 2 | 0.0 |
Protein Conformation | 10 | 0.0 |
Receptors, Chemokine/metabolism | 2 | 1.0 |
Blood Platelets/metabolism | 13 | 7.0 |
Megakaryocytes/metabolism | 2 | 5.0 |
Rats | 22 | 0.0 |
Inflammation | 2 | 0.0 |
Models, Biological | 3 | 0.0 |
Antithrombin III | 3 | 5.0 |
Peptide Hydrolases/blood | 3 | 6.0 |
Sequence Analysis, DNA | 3 | 0.0 |
*Cardiopulmonary Bypass | 3 | 3.0 |
Microscopy, Electron, Scanning | 5 | 1.0 |
Chromatography, Affinity | 8 | 1.0 |
Kinetics | 20 | 0.0 |
Platelet Aggregation/drug effects | 18 | 8.0 |
6-Ketoprostaglandin F1 alpha/blood | 3 | 16.0 |
Adolescent | 40 | 0.0 |
Arteriosclerosis/*blood | 2 | 9.0 |
Biological Markers/blood | 6 | 0.0 |
Hypertension, Pulmonary/*blood | 3 | 60.0 |
Myocardial Infarction/*blood | 6 | 9.0 |
P-Selectin/*blood | 2 | 6.0 |
Prognosis | 3 | 0.0 |
Solubility | 2 | 0.0 |
Thromboxane B2/blood | 10 | 25.0 |
Double-Blind Method | 5 | 0.0 |
Platelet Activation/*drug effects | 6 | 9.0 |
Coronary Disease/*blood/physiopathology | 2 | 28.0 |
Platelet Factor 4/*analysis | 46 | 95.0 |
Adenosine Triphosphate/blood | 4 | 14.0 |
Temperature | 3 | 0.0 |
Cell Differentiation/drug effects | 3 | 0.0 |
Child | 17 | 0.0 |
Child, Preschool | 6 | 0.0 |
Drug Combinations | 4 | 0.0 |
Infant | 2 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Platelet Factor 4/*pharmacology | 22 | 81.0 |
Stromal Cells/cytology | 2 | 4.0 |
Vascular Endothelial Growth Factor A | 4 | 0.0 |
Vascular Endothelial Growth Factors | 4 | 0.0 |
Blood Platelets/immunology | 2 | 2.0 |
Enzyme Activation | 2 | 0.0 |
Megakaryocytes/*cytology | 6 | 11.0 |
Sequence Homology, Amino Acid | 8 | 0.0 |
Platelet Count | 38 | 8.0 |
Platelet-Derived Growth Factor/*metabolism | 2 | 8.0 |
Sensitivity and Specificity | 3 | 0.0 |
Tumor Markers, Biological/*blood | 4 | 0.0 |
Clinical Trials | 4 | 0.0 |
Macaca mulatta | 2 | 0.0 |
Megakaryocytes/*cytology/drug effects | 2 | 16.0 |
*Neoplasm Proteins | 2 | 0.0 |
Platelet Factor 4/physiology | 7 | 100.0 |
*Receptors, Cytokine | 2 | 1.0 |
Recombinant Proteins/pharmacology | 7 | 0.0 |
Thrombin/physiology | 4 | 11.0 |
Transforming Growth Factor beta/physiology | 2 | 2.0 |
Factor Xa/*antagonists & inhibitors | 2 | 5.0 |
Thrombin/*antagonists & inhibitors | 3 | 25.0 |
Blood Platelets/*physiology | 27 | 15.0 |
Epinephrine/*pharmacology | 2 | 7.0 |
Lipopolysaccharides/pharmacology | 5 | 0.0 |
Antigens, CD34/*blood | 2 | 2.0 |
Platelet Factor 4/biosynthesis | 2 | 40.0 |
beta-Thromboglobulin/biosynthesis | 2 | 50.0 |
Chemokines, CXC/*genetics | 2 | 6.0 |
Electrophoresis, Gel, Pulsed-Field | 2 | 0.0 |
*Intercellular Signaling Peptides and Proteins | 2 | 0.0 |
Phylogeny | 2 | 0.0 |
Platelet Factor 4/genetics | 2 | 40.0 |
Restriction Mapping | 3 | 0.0 |
Thrombocytopenia/*chemically induced/*immunology | 3 | 100.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Gene Expression | 7 | 0.0 |
Enzyme-Linked Immunosorbent Assay/methods | 3 | 1.0 |
False Negative Reactions | 2 | 1.0 |
Platelet Factor 4 | 3 | 60.0 |
Blood Platelets/cytology/*physiology | 2 | 18.0 |
Cell Division | 4 | 0.0 |
Gene Expression Regulation | 4 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Transcription, Genetic | 4 | 0.0 |
Cell Differentiation | 3 | 0.0 |
Cell Line | 10 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Platelet Factor 4/*chemistry/metabolism | 2 | 100.0 |
Promoter Regions (Genetics) | 6 | 0.0 |
Sequence Homology, Nucleic Acid | 8 | 0.0 |
Transfection | 5 | 0.0 |
Tumor Cells, Cultured | 9 | 0.0 |
Cell Adhesion | 6 | 0.0 |
Down-Regulation | 2 | 0.0 |
Chemokines/*physiology | 2 | 6.0 |
Cell Cycle/drug effects | 2 | 0.0 |
Fibroblast Growth Factor 2/pharmacology | 2 | 0.0 |
Glycosaminoglycans/metabolism | 3 | 6.0 |
Platelet Factor 4/*physiology | 12 | 100.0 |
Umbilical Veins | 4 | 0.0 |
Platelet Aggregation/*drug effects | 5 | 3.0 |
Laboratory Techniques and Procedures | 2 | 6.0 |
Platelet Factor 4/immunology | 7 | 87.0 |
*Biocompatible Materials | 4 | 11.0 |
Blood Coagulation/drug effects | 6 | 5.0 |
Blood Platelets/drug effects | 3 | 11.0 |
*Extracorporeal Circulation | 2 | 8.0 |
Asthma/immunology | 2 | 5.0 |
Chemotaxis | 3 | 1.0 |
Platelet Activation/physiology | 4 | 14.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Biological Markers | 6 | 0.0 |
Logistic Models | 2 | 0.0 |
*Heart Valve Prosthesis | 2 | 10.0 |
Fibrinolysis | 3 | 1.0 |
Platelet Factor 4/*genetics | 12 | 92.0 |
Sequence Deletion | 2 | 0.0 |
Stimulation, Chemical | 3 | 0.0 |
Thrombin/*pharmacology | 2 | 1.0 |
Drug Interactions | 2 | 0.0 |
Heparin Antagonists/pharmacology | 5 | 71.0 |
Partial Thromboplastin Time | 10 | 5.0 |
Protamines/*pharmacology | 4 | 33.0 |
Thrombin Time | 3 | 14.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Hematopoietic Stem Cells/*drug effects | 2 | 3.0 |
Mice, Inbred BALB C | 6 | 0.0 |
Peptides/*pharmacology | 2 | 0.0 |
Risk Factors | 9 | 0.0 |
*Chromosomes, Human, Pair 4 | 4 | 1.0 |
Electrostatics | 2 | 1.0 |
Heparin/metabolism | 6 | 4.0 |
Ligands | 2 | 0.0 |
Protein C/*metabolism | 3 | 1.0 |
Blood Coagulation | 3 | 1.0 |
Biotinylation | 2 | 1.0 |
Cross-Linking Reagents | 2 | 0.0 |
Heparin/*adverse effects/*immunology | 2 | 100.0 |
Echocardiography | 2 | 0.0 |
Thromboembolism/epidemiology/etiology | 2 | 28.0 |
Analysis of Variance | 5 | 0.0 |
Cross-Over Studies | 2 | 0.0 |
Thromboembolism/*etiology | 2 | 28.0 |
Antiplasmin/analysis | 2 | 5.0 |
Antithrombin III/analysis | 6 | 3.0 |
Blood Coagulation/*physiology | 2 | 1.0 |
Echocardiography, Transesophageal | 2 | 14.0 |
Fibrin Fibrinogen Degradation Products/analysis | 5 | 3.0 |
Fibrinopeptide A/analysis | 9 | 21.0 |
Peptide Hydrolases/analysis | 3 | 2.0 |
Antigens, CD/*genetics/immunology | 2 | 11.0 |
DNA Primers/chemistry | 2 | 0.0 |
Immunoglobulin G/*immunology | 2 | 2.0 |
Platelet Activation/*immunology | 2 | 11.0 |
Polymorphism, Genetic | 2 | 0.0 |
Receptors, IgG/*genetics/immunology | 2 | 100.0 |
Anticoagulants/*pharmacology | 2 | 2.0 |
Heparin/pharmacology | 5 | 2.0 |
Heparin/*adverse effects/chemistry | 2 | 100.0 |
Colony-Forming Units Assay | 3 | 0.0 |
Fetal Blood/cytology | 2 | 1.0 |
Interleukin-8/*pharmacology | 2 | 11.0 |
Cardiopulmonary Bypass | 2 | 4.0 |
*Fibrinolysis | 8 | 6.0 |
Antithrombin III/metabolism | 6 | 5.0 |
Blood Coagulation Factors/*metabolism | 8 | 10.0 |
Fibrinopeptide A/metabolism | 6 | 24.0 |
Peptide Hydrolases/metabolism | 2 | 1.0 |
Plasmin/metabolism | 2 | 2.0 |
Blood Platelets/*drug effects | 11 | 28.0 |
Fibrinolysis/*drug effects | 2 | 3.0 |
Platelet Aggregation Inhibitors/pharmacology | 3 | 4.0 |
Thrombosis/etiology/prevention & control | 2 | 33.0 |
Aspirin/therapeutic use | 3 | 7.0 |
Thrombin/*biosynthesis | 2 | 6.0 |
Peptide Fragments/analysis | 2 | 0.0 |
Prothrombin/analysis | 2 | 2.0 |
Thrombin/biosynthesis | 3 | 7.0 |
Blood Proteins/*metabolism | 2 | 1.0 |
Blood Platelets/*immunology | 2 | 2.0 |
Cytokines/*pharmacology | 3 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 2 | 0.0 |
Fibrinogen/analysis | 4 | 2.0 |
Plasminogen/analysis | 2 | 11.0 |
Platelet Count/drug effects | 5 | 13.0 |
Serotonin/blood | 9 | 23.0 |
DNA/genetics | 4 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Coronary Artery Bypass | 2 | 3.0 |
Fibrinolysis/*physiology | 2 | 2.0 |
Glycosaminoglycans/*physiology | 2 | 50.0 |
*Hematopoiesis | 3 | 1.0 |
Oligopeptides/pharmacology | 2 | 1.0 |
Thrombin/pharmacology | 5 | 2.0 |
Coronary Angiography | 2 | 0.0 |
Exercise Test | 4 | 1.0 |
Plasminogen Activator Inhibitor 1/blood | 2 | 1.0 |
Iodine Radioisotopes | 3 | 0.0 |
Heparitin Sulfate/*metabolism | 2 | 6.0 |
Platelet Factor 4/metabolism/*pharmacology | 2 | 100.0 |
Protamines/pharmacology | 2 | 13.0 |
Anticoagulants/*therapeutic use | 2 | 4.0 |
Heparin/*therapeutic use | 2 | 8.0 |
Injections, Intravenous | 4 | 0.0 |
Myocardial Infarction/blood/*drug therapy | 2 | 14.0 |
Biological Markers/*blood | 4 | 2.0 |
Macromolecular Substances | 12 | 0.0 |
beta-Thromboglobulin/pharmacology | 2 | 66.0 |
Bone Marrow Cells | 6 | 1.0 |
Heparin/*pharmacology | 12 | 8.0 |
Megakaryocytes/cytology/*drug effects | 2 | 20.0 |
Heparin/*metabolism | 3 | 3.0 |
Magnetic Resonance Spectroscopy | 8 | 1.0 |
*Protein Folding | 3 | 2.0 |
*Protein Structure, Secondary | 3 | 2.0 |
Carbon Radioisotopes | 2 | 2.0 |
Blood Coagulation Factors/analysis | 5 | 8.0 |
Follow-Up Studies | 4 | 0.0 |
Hematopoiesis/*drug effects | 3 | 3.0 |
Granulocytes/physiology | 3 | 15.0 |
Heparin/administration & dosage | 3 | 13.0 |
Thromboplastin/*metabolism | 2 | 1.0 |
Receptors, Interleukin-8A | 4 | 12.0 |
Platelet Adhesiveness/drug effects | 2 | 4.0 |
beta-Thromboglobulin/*analysis | 32 | 84.0 |
Heart Catheterization | 3 | 4.0 |
Hemodynamic Processes/drug effects | 2 | 1.0 |
Hemostasis/*drug effects | 4 | 6.0 |
Platelet Aggregation Inhibitors/*therapeutic use | 4 | 16.0 |
Chronic Disease | 8 | 0.0 |
Blotting, Northern | 3 | 0.0 |
Blotting, Southern | 2 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Escherichia coli | 2 | 0.0 |
Hydrogen Bonding | 2 | 1.0 |
Models, Structural | 2 | 1.0 |
RANTES | 2 | 22.0 |
Cardiac Surgical Procedures | 2 | 10.0 |
Heparin Antagonists/*pharmacology | 2 | 40.0 |
Recombinant Proteins | 2 | 0.0 |
Whole Blood Coagulation Time | 3 | 17.0 |
Endothelium, Vascular/cytology/drug effects/*metabolism | 2 | 2.0 |
P-Selectin | 4 | 7.0 |
*Chemokines, CXC | 2 | 3.0 |
Wound Healing | 2 | 1.0 |
Complement 3a/metabolism | 2 | 12.0 |
Leukocyte Count | 4 | 0.0 |
Platelet Adhesiveness | 2 | 4.0 |
Thrombospondins | 4 | 3.0 |
Eosinophils/*cytology | 3 | 23.0 |
Plasma | 2 | 3.0 |
Chemistry, Physical | 3 | 2.0 |
Circular Dichroism | 3 | 0.0 |
Platelet Factor 4/*chemistry | 3 | 100.0 |
Heart Defects, Congenital/*blood/complications | 2 | 100.0 |
Regression Analysis | 6 | 0.0 |
Hydrogen-Ion Concentration | 5 | 0.0 |
Platelet-Derived Growth Factor/*analysis | 2 | 25.0 |
Chromosome Mapping | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Interleukin-2/*therapeutic use | 2 | 1.0 |
Blood Coagulation Factors/*analysis | 21 | 25.0 |
Neoplasm Staging | 4 | 0.0 |
Angina Pectoris/blood | 2 | 14.0 |
*Exertion | 6 | 3.0 |
*Physical Endurance | 2 | 4.0 |
Glycoproteins/*metabolism | 2 | 1.0 |
Heparan Sulfate Proteoglycan | 2 | 6.0 |
Cations | 2 | 2.0 |
Heparin, Low-Molecular-Weight/antagonists & inhibitors/*pharmacology | 2 | 100.0 |
Injections, Subcutaneous | 3 | 0.0 |
Platelet Aggregation/physiology | 4 | 10.0 |
Thromboembolism/etiology | 3 | 20.0 |
Drug Therapy, Combination | 3 | 0.0 |
Calcium/metabolism | 4 | 0.0 |
Platelet Membrane Glycoproteins/metabolism | 2 | 2.0 |
Peptides/*physiology | 2 | 4.0 |
Blood Platelets/*drug effects/physiology | 2 | 18.0 |
Cholesterol/blood | 6 | 0.0 |
Creatinine/metabolism | 2 | 2.0 |
Hemoglobin A, Glycosylated/analysis | 3 | 0.0 |
Triglycerides/blood | 7 | 0.0 |
Anticoagulants/pharmacology | 3 | 4.0 |
Blood Specimen Collection/*methods | 2 | 8.0 |
Citrates/pharmacology | 2 | 11.0 |
Citric Acid | 3 | 8.0 |
Endothelium, Vascular/metabolism | 3 | 1.0 |
Platelet Factor 4/*analysis/metabolism | 2 | 100.0 |
*Gene Expression Regulation | 3 | 0.0 |
Inflammation/*metabolism | 2 | 3.0 |
Blood Coagulation/*drug effects | 4 | 3.0 |
Immunoassay | 3 | 1.0 |
*Blood Preservation | 7 | 12.0 |
L-Lactate Dehydrogenase/blood | 4 | 3.0 |
Blood Platelets/*secretion | 3 | 27.0 |
Migraine/*blood | 2 | 28.0 |
beta-Thromboglobulin/*metabolism | 8 | 80.0 |
Infusions, Intravenous | 3 | 0.0 |
Factor VIII/analysis | 2 | 1.0 |
Interleukin-8/metabolism | 2 | 1.0 |
Peptides/metabolism | 2 | 0.0 |
Rabbits | 8 | 0.0 |
Antigens | 4 | 4.0 |
Erythrocyte Count | 2 | 2.0 |
Hemoglobins/analysis | 2 | 0.0 |
Hemostasis/*physiology | 3 | 5.0 |
Kidney Failure, Chronic/*blood | 5 | 7.0 |
Renal Dialysis | 4 | 1.0 |
Chemotaxis, Leukocyte/drug effects | 2 | 2.0 |
Receptors, Immunologic/*metabolism | 2 | 1.0 |
Cell Adhesion/drug effects | 4 | 0.0 |
Cell Separation | 2 | 0.0 |
Filtration/*instrumentation | 2 | 40.0 |
Fibrin Fibrinogen Degradation Products/*metabolism | 2 | 9.0 |
Fibrinopeptide A/*metabolism | 2 | 28.0 |
Peptide Fragments/*metabolism | 2 | 1.0 |
*Partial Thromboplastin Time | 3 | 16.0 |
Hydrogen | 4 | 19.0 |
Magnetic Resonance Spectroscopy/methods | 3 | 6.0 |
Antithrombins/*metabolism | 2 | 20.0 |
Chromatography, Ion Exchange | 3 | 0.0 |
Tritium | 2 | 0.0 |
Amniocentesis | 2 | 2.0 |
Amniotic Fluid/*chemistry | 2 | 4.0 |
Pregnancy Trimester, Second | 2 | 0.0 |
Radioimmunoassay | 20 | 1.0 |
alpha-Fetoproteins/analysis | 2 | 0.0 |
Neutrophils/drug effects/*physiology | 2 | 3.0 |
Heparin/*blood | 4 | 50.0 |
Eosinophil Granule Proteins | 2 | 0.0 |
*Ribonucleases | 2 | 0.0 |
Uremia/blood/*therapy | 2 | 33.0 |
Blood Proteins/*analysis | 2 | 1.0 |
*Platelet Aggregation/drug effects | 3 | 9.0 |
Blood Platelets/physiology | 2 | 3.0 |
Fibrin Fibrinogen Degradation Products/metabolism | 2 | 2.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Chromatography, Gel | 3 | 0.0 |
Oxidation-Reduction | 2 | 0.0 |
Fibrinopeptide A/*analysis | 6 | 35.0 |
Administration, Oral | 2 | 0.0 |
Molecular Weight | 11 | 0.0 |
Prothrombin/antagonists & inhibitors | 2 | 28.0 |
Cold | 2 | 1.0 |
*Histamine Release | 2 | 16.0 |
Autoradiography | 2 | 0.0 |
DNA Restriction Enzymes | 3 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
beta-Thromboglobulin/*genetics | 2 | 100.0 |
Acute Disease | 4 | 0.0 |
Severity of Illness Index | 2 | 0.0 |
Vascular Diseases/*blood | 3 | 42.0 |
Bronchoalveolar Lavage Fluid/chemistry | 2 | 3.0 |
Adenosine Triphosphate/metabolism | 2 | 0.0 |
Fibronectins/*blood | 3 | 11.0 |
Creatinine/blood | 3 | 0.0 |
Fluorescent Antibody Technique | 7 | 0.0 |
Species Specificity | 4 | 0.0 |
Phenotype | 2 | 0.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Angina Pectoris/*blood | 3 | 14.0 |
Coronary Disease/*blood | 5 | 7.0 |
Heparin/blood | 3 | 21.0 |
*Heparin Antagonists | 4 | 100.0 |
Mathematics | 2 | 1.0 |
Thermodynamics | 2 | 0.0 |
Administration, Inhalation | 2 | 1.0 |
Dust | 2 | 6.0 |
Thromboxane B2/*blood | 2 | 18.0 |
Acrylic Resins | 2 | 8.0 |
Heparin/*administration & dosage | 2 | 6.0 |
Antibodies, Monoclonal/diagnostic use | 3 | 0.0 |
*Platelet Aggregation | 9 | 10.0 |
Myeloproliferative Disorders/*blood | 2 | 22.0 |
Blood Proteins/analysis | 2 | 1.0 |
Risk | 4 | 0.0 |
*Platelet Factor 4 | 4 | 100.0 |
Platelet Function Tests/methods | 2 | 40.0 |
Polycythemia Vera/blood | 2 | 15.0 |
Microscopy, Electron | 9 | 0.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Plateletpheresis | 3 | 33.0 |
Blood Platelets/analysis | 3 | 18.0 |
Chromatography, Agarose | 2 | 4.0 |
Half-Life | 7 | 1.0 |
Hypertension/*blood | 2 | 3.0 |
Epoprostenol/pharmacology | 6 | 24.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Amino Acids/analysis | 6 | 2.0 |
Cerebral Infarction/*blood | 2 | 22.0 |
Prothrombin Time | 2 | 1.0 |
Blood Platelets/physiology/*ultrastructure | 2 | 50.0 |
Factor VIII/metabolism | 2 | 2.0 |
*Cardiac Pacing, Artificial | 2 | 22.0 |
beta-Thromboglobulin/*physiology | 2 | 100.0 |
Osmolar Concentration | 2 | 0.0 |
Immunoenzyme Techniques | 5 | 0.0 |
Blood Platelets/*physiology/ultrastructure | 2 | 25.0 |
Blood Proteins/metabolism | 2 | 0.0 |
Receptors, Thrombin | 2 | 4.0 |
*Genes, Structural | 2 | 0.0 |
Coronary Disease/blood | 2 | 7.0 |
Pedigree | 2 | 0.0 |
Iloprost | 2 | 40.0 |
Blood Platelets/cytology | 2 | 8.0 |
Fibrinogen/*analysis | 4 | 9.0 |
Megakaryocytes/*analysis | 2 | 50.0 |
Blood Platelets/metabolism/*physiology | 3 | 23.0 |
Chemistry | 2 | 0.0 |
Myocardial Infarction/blood | 2 | 5.0 |
*Blood Coagulation Tests | 2 | 8.0 |
Centrifugation | 2 | 2.0 |
Chromatography | 2 | 1.0 |
Fibrinogen/metabolism | 4 | 1.0 |
6-Ketoprostaglandin F1 alpha/biosynthesis | 2 | 11.0 |
Kidney/*metabolism | 2 | 1.0 |
Blood Platelets/*analysis/ultrastructure | 2 | 66.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
Platelet Factor 4/isolation & purification/*physiology | 2 | 100.0 |
Beta-Globulins/*metabolism | 7 | 63.0 |
Blood Glucose/analysis | 2 | 0.0 |
Fibrinogen/*metabolism | 2 | 2.0 |
Liver Diseases/*blood | 2 | 6.0 |
Microscopy, Phase-Contrast | 2 | 2.0 |
Blood Platelets/drug effects/*metabolism | 2 | 2.0 |
Blood Specimen Collection/methods | 2 | 10.0 |
Anticoagulants/therapeutic use | 3 | 4.0 |
Epitopes | 3 | 0.0 |
Age Factors | 2 | 0.0 |
Immune Sera | 2 | 0.0 |
Beta-Globulins/*analysis | 20 | 48.0 |
Pilot Projects | 2 | 0.0 |
Blood Platelets/*analysis | 3 | 17.0 |
Heparin Antagonists | 3 | 100.0 |
Blood Coagulation Factors/*physiology | 2 | 8.0 |
Blood Platelets/drug effects/*physiology | 2 | 4.0 |
Diabetes Mellitus/blood | 3 | 4.0 |
Radioimmunoassay/methods | 3 | 1.0 |
Factor X/antagonists & inhibitors | 3 | 33.0 |
Factor Xa | 2 | 10.0 |
Aorta | 2 | 1.0 |
Heparin/*diagnostic use | 2 | 25.0 |
Platelet Factor 4/immunology/*metabolism | 3 | 100.0 |
Sodium Dodecyl Sulfate | 2 | 3.0 |
beta-Thromboglobulin | 3 | 75.0 |
*Blood Coagulation Factors | 4 | 13.0 |
Sulfinpyrazone/*therapeutic use | 2 | 100.0 |
Uremia/blood | 2 | 11.0 |
Diabetes Mellitus/*blood/drug therapy | 2 | 8.0 |
Insulin/therapeutic use | 2 | 1.0 |
Serotonin/secretion | 2 | 8.0 |
Blood Cell Count | 3 | 1.0 |
*Blood Platelets | 6 | 28.0 |
Anticoagulants/*administration & dosage | 2 | 4.0 |
Immunoelectrophoresis | 2 | 0.0 |
Blood Coagulation Factors/*secretion | 2 | 50.0 |
Platelet Factor 4/*secretion | 2 | 66.0 |
Kidney Failure, Chronic/blood | 2 | 8.0 |
beta-Thromboglobulin/immunology/*metabolism | 2 | 100.0 |
*Blood Proteins | 2 | 2.0 |
Malondialdehyde/blood | 2 | 3.0 |
Platelet Factor 3/metabolism | 2 | 66.0 |
